Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Byoung Heon Kang
Title Novel in vivo pan-Hsp90 family protein inhibitor, Panvotinib-401, showed potent anticancer activities without HSF1 activation
Abstract Text


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Panvotinib-401 Panvotinib-401 1 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
Panvotinib-401 HSP90 Inhibitor 35 Panvotinib-401 is a small molecule Hsp90 inhibitor that is mitochondrial inner membrane-permeable, resulting in cancer cell toxicity (AACR, Cancer Res: April 2016; Volume 57, Abstract #3896).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Panvotinib-401 Preclinical Actionable In a preclinical study, Panvotinib-401 demonstrated cancer-selective cytotoxicity in transformed cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #3896). detail...